Madison, WI (June 14, 2010) Despite a sluggish economy, Quincy Bioscience is experiencing consistent growth. This month the Madison, WI based biotech company relocates its corporate offices to a facility four times the size of its former location. The move will support the rapid growth of the company whose mission is to help fight the deleterious effects of human aging with its patented calcium-binding technology.
Quincy Bioscience (http://www.quincybioscience.com) made a significant move to a 25,000 square feet office space on Madison’s west side. This will allow the company to continue to add new talent to existing departments as well accommodates the future growth of the company.
“There is a huge need in the marketplace for improving the health of those over 40 years old. The dramatic changes in the economy and our healthcare system are placing more responsibility especially on baby boomers to stay healthy. Quincy Bioscience is positioned to help meet this demand” explains Mark Underwood, President of Quincy Bioscience.
Mike Beaman co-founder and CEO of Quincy Bioscience, expressed his overall excitement toward the expansion, “Through the tremendous sales growth of Prevagen (http://www.prevagen.com), and our continued commitment to research and development, we are creating jobs that help support the local economy as well as playing an increasingly vital role in improving the quality of life for so many. We are very excited about the future of Quincy Bioscience.”
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company’s products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.
